MI-192 is a selective HDAC2 and HDAC3 inhibitor with IC50 values of 30 nM and 16 nM, respectively. It exhibits greater selectivity for HDAC2/3 over other HDAC isomers and induces apoptosis in myeloid leukemic cells, indicating potential therapeutic use in leukemia and as an anti-stroke agent [1] [2].

MI-192, at concentrations ranging from 0.15 to 1 μM over a period of 72 hours, both induces differentiation and exerts cytotoxic effects through apoptosis promotion in the acute myeloid leukemia cell lines U937, HL60, and Kasumi-1 [1]. Specifically, apoptosis analysis revealed that MI-192, at concentrations of 150 nM, 300 nM, 500 nM, and 1 μM, significantly induced apoptosis in HL60 and Kasumi-1 cells after a 72-hour incubation [1].

MI-192 (40 mg/kg; i.p.; once a day for 3 days) exhibits neuroprotective effects in adult male outbred CD-1 mice (20-25 g) with photothrombotic stroke (PTS). It significantly reduces PTS-induced brain infarction volume, improves forelimb functional symmetry, decreases PTS-induced apoptosis and α-tubulin acetylation, and increases GAP-43 expression in the affected cerebral cortex.